Trial Profile
A Phase 1/2 Study of ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma in Conjunction With Rituximab
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Inbakicept (Primary) ; Inbakicept (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Altor BioScience Corporation
- 04 May 2021 According to an ImmunityBio Media Release, data from this trial were published in the American Association for Cancer Research journal Clinical Cancer Research.
- 04 May 2021 Results presented in an ImmunityBio Media Release.
- 08 Apr 2021 Results published in the Clinical Cancer Research